Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

In memory of Milena Kemali: the scientist, the person.

Hökfelt T, Polani PE, Polani N, Bartholini G, Bartholini E.

Neurosci Biobehav Rev. 1996 Winter;20(4):555-6. No abstract available. Erratum in: Neurosci Biobehav Rev 1997 May;21(3):380.

PMID:
8994193
2.

Difluoromethyl ornithine protects against the neurotoxic effects of intrastriatally administered N-methyl-D-aspartate in vivo.

Porcella A, Fage D, Voltz C, Carter C, Scatton B, Bartholini G.

Eur J Pharmacol. 1991 Jun 25;199(2):267-9.

PMID:
1835443
3.

The psychopharmacology of GABA synapses: update 1989.

Lloyd KG, Pichat P, Scatton B, Zivkovic B, Morselli PL, Bartholini G.

J Neural Transm Suppl. 1990;29:13-28.

PMID:
2162909
4.

The gabaergic hypothesis of depression.

Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G.

Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3-4):341-51. Review.

PMID:
2664889
5.
6.

Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat.

Scatton B, Lloyd KG, Zivkovic B, Dennis T, Claustre Y, Dedek J, Arbilla S, Langer SZ, Bartholini G.

J Pharmacol Exp Ther. 1987 Apr;241(1):251-7.

PMID:
3033204
7.

Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile.

Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G.

J Pharmacol Exp Ther. 1987 Apr;241(1):245-50.

PMID:
3033203
8.

GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.

Bartholini G, Scatton B, Zivkovic B, Lloyd KG.

Adv Neurol. 1987;45:79-83.

PMID:
3030072
9.

GABA and affective disorders.

Lloyd KG, Morselli PL, Bartholini G.

Med Biol. 1987;65(2-3):159-65. Review.

PMID:
2821330
10.

Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.

Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G.

J Pharmacol Exp Ther. 1986 May;237(2):649-58.

PMID:
2871178
11.

Non-benzodiazepine anxiolytics: potential activity of phenylpiperazines without 3H-diazepam displacing action.

Lloyd KG, Depoortere H, Scatton B, Schoemaker H, Zivkovic B, Manoury P, Langer SZ, Morselli PL, Bartholini G.

Pharmacol Biochem Behav. 1985 Oct;23(4):645-52.

PMID:
2866545
12.

Progabide reverses the nigral substance P reduction induced by chronic impairment of dopaminergic transmission.

Zivkovic B, Oblin A, Bartholini G.

Eur J Pharmacol. 1985 Jun 7;112(2):253-5.

PMID:
2411575
13.

The GABA hypothesis of depression and antidepressant drug action.

Bartholini G, Lloyd KG, Scatton B, Zivkovic B, Morselli PL.

Psychopharmacol Bull. 1985;21(3):385-8. No abstract available.

PMID:
2994153
14.

Influence of GABA mimetics and lithium on biochemical manifestations of striatal dopamine target cell hypersensitivity.

Scatton B, Fage D, Oblin A, Zivkovic B, Arbilla S, Langer SZ, Bartholini G.

Psychopharmacology Suppl. 1985;2:39-45.

PMID:
2987906
15.

GABA receptor agonists: pharmacological spectrum and therapeutic actions.

Bartholini G.

Med Res Rev. 1985 Jan-Mar;5(1):55-75. Review.

PMID:
2984490
16.

Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P.

Oblin A, Zivkovic B, Bartholini G.

Eur J Pharmacol. 1984 Oct 1;105(1-2):175-7.

PMID:
6208042
17.
18.

Pharmacology of the GABAergic system: effects of progabide, a GABA receptor agonist.

Bartholini G.

Psychoneuroendocrinology. 1984;9(2):135-40.

PMID:
6089242
19.

The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials.

Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B, Broekkamp C, Worms P, Bartholini G.

Pharmacol Biochem Behav. 1983 Jun;18(6):957-66.

PMID:
6351106
20.

GABA system, GABA receptor agonists and dyskinesia.

Bartholini G.

Mod Probl Pharmacopsychiatry. 1983;21:143-54. Review. No abstract available.

PMID:
6318094
21.

Pharmacological and therapeutic actions of GABA receptor agonists.

Zivkovic B, Scatton B, Worms P, Lloyd KG, Bartholini G.

J Neural Transm Suppl. 1983;18:319-26.

PMID:
6308150
22.

[3H]Haloperidol labels brain dopamine receptors after its injection into the internal carotid artery of the rat.

D'Ambrosio A, Zivkovic B, Bartholini G.

Brain Res. 1982 Apr 29;238(2):470-4.

PMID:
7093669
23.
24.

gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas.

Scatton B, Zivkovic B, Dedek J, Lloyd KG, Constantinidis J, Tissot R, Bartholini G.

J Pharmacol Exp Ther. 1982 Mar;220(3):678-88. No abstract available.

PMID:
6278130
25.

gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra.

Worms P, Depoortere H, Durand A, Morselli PL, Lloyd KG, Bartholini G.

J Pharmacol Exp Ther. 1982 Mar;220(3):660-71.

PMID:
6278129
26.

gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor.

Lloyd KG, Arbilla S, Beaumont K, Briley M, De Montis G, Scatton B, Langer SZ, Bartholini G.

J Pharmacol Exp Ther. 1982 Mar;220(3):672-7.

PMID:
6121050
27.

Cortical modulation of striatal function.

Scatton B, Worms P, Lloyd KG, Bartholini G.

Brain Res. 1982 Jan 28;232(2):331-43.

PMID:
6200179
28.

Drug-induced changes of epinephrine turnover in the rat hypothalamus.

Scatton B, Bartholini G.

Life Sci. 1981 Sep 14;29(11):1161-70. No abstract available.

PMID:
6116998
29.

Interactions between GABA, dopamine, acetylcholine, and glutamate-containing neurons in the extrapyramidal and limbic systems.

Bartholini G, Scatton B, Worms P, Zivkovic B, Lloyd KG.

Adv Biochem Psychopharmacol. 1981;30:119-28. No abstract available.

PMID:
6120626
30.
31.

New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide.

Kaplan JP, Raizon BM, Desarmenien M, Feltz P, Headley PM, Worms P, Lloyd KG, Bartholini G.

J Med Chem. 1980 Jun;23(6):702-4.

PMID:
7392039
32.

Modulation by GABA of cholinergic transmission in the striatum.

Scatton B, Bartholini G.

Brain Res. 1980 Feb 3;183(1):211-6. No abstract available.

PMID:
6244048
33.

The potential of GABA-mimetics in the therapy of extrapyramidal disorders.

Bartholini G, Lloyd KG.

J Neural Transm Suppl. 1980;(16):229-38. Review.

PMID:
6107332
34.
35.

Effect of clonidine on utilization and potassium-evoked release of adrenaline in rat brain areas.

Scatton B, Pelayo F, Dubocovich ML, Langer SZ, Bartholini G.

Brain Res. 1979 Oct 26;176(1):197-201. No abstract available.

PMID:
487178
36.

Increase in striatal acetylcholine levels by GABA mimetic drugs: lack of involvement of the nigro-striatal dopaminergic neurons.

Scatton B, Bartholini G.

Eur J Pharmacol. 1979 Jun;56(1-2):181-2. No abstract available.

PMID:
467509
37.

[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].

Bartholini G.

Schweiz Arch Neurol Neurochir Psychiatr. 1979;125(2):265-9. French.

PMID:
45343
38.

Gamma-aminobutyric-acid analogues.

Lloyd KG, Kaplan JP, Bartholini G.

Lancet. 1978 Nov 4;2(8097):1004. No abstract available.

PMID:
81985
39.

[Recent data on the mode of action of neuroleptics].

Bartholini G.

Actual Pharmacol (Paris). 1978;30:35-47. Review. French. No abstract available.

PMID:
28640
40.

Evidence for an intrastriatal GABA-ergic influence on dopamine neurones of the cat.

Bartholini G, Stadler H.

Neuropharmacology. 1977 May;16(5):343-7. No abstract available.

PMID:
865661
41.

Interaction of GABA, dopamine, and acetylcholine in cat striatum: pharmacological considerations [proceedings].

Bartholini G.

Psychopharmacol Bull. 1977 Jan;13(1):32-3. No abstract available.

PMID:
834814
42.

Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.

Bartholini G.

Adv Biochem Psychopharmacol. 1977;16:607-11. No abstract available.

PMID:
18902
43.

Interaction of dopaminergic and cholinergic neurons in the extrapyramidal and limbic systems.

Bartholini G, Stadler H, Gadea-Ciria M, Lloyd KG.

Adv Biochem Psychopharmacol. 1977;16:391-5. No abstract available.

PMID:
18888
44.

The use of the push-pull cannula to estimate the dynamics of acetylcholine and catecholamines within various brain areas.

Bartholini G, Stadler H, Ciria MG, Lloyd KG.

Neuropharmacology. 1976 Sep;15(9):515-9. No abstract available.

PMID:
980227
45.
46.

Monoaminergic drugs: general pharmacology.

Haefely W, Bartholini G, Pletscher A.

Pharmacol Ther B. 1976;2(1):185-218. Review. No abstract available.

PMID:
817330
47.
48.

Lysergic acid diethylamide: evidence for stimulation of cerebral dopamine receptors.

Prada MD, Saner A, Burkark WP, Bartholini G, Pletscher A.

Brain Res. 1975 Aug 22;94(1):67-73.

PMID:
1148867
49.

Drug-induced changes of dopamine turnover in striatum and limbic system of the rat.

Bartholini G, Keller HH, Pletscher A.

J Pharm Pharmacol. 1975 Jun;27(6):439-42. No abstract available.

PMID:
237095
50.

The effect of drugs on the release of endogenous catecholamines into the perfusate of discrete brain areas of the cat in vivo.

Lloyd KG, Bartholini G.

Experientia. 1975 May 15;31(5):560-2. No abstract available.

PMID:
1140255

Supplemental Content

Loading ...
Support Center